Clin2
NCT07446439Possibly a fitRecruiting

Tradipitant for nausea from weight loss injections

Nausea and VomitingObesity

Treatments studied

Part of Hormones & metabolism clinical trials.

This study tests whether the drug tradipitant can help reduce nausea and vomiting caused by weight loss injections like Ozempic or Wegovy. If you have these side effects and are not diabetic, you may be eligible.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 3
Enrollment
280 people
Ages
18 years to 65 years
Study type
Interventional

Who can take part

  • You are currently taking a GLP-1 weight loss medication (like Ozempic, Wegovy, or Mounjaro) and have nausea or vomiting from it.
  • You do not have type 1 or type 2 diabetes.
  • Your body mass index (BMI) is between 25 and 40. This means you are in the overweight or obese range.
  • You do not have other stomach or bowel problems that could cause nausea or vomiting.
  • You have not had a bad reaction to certain nausea medications (NK-1 receptor antagonists) or GLP-1 medications before.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07467447Recruiting· Phase 2
Testing a weight-loss drug for people with obesity or overweight

This trial tests whether an experimental drug (LY3437943) can help people with obesity or overweight lose weight. It compares the drug to a placebo (inactive shot), and you must be willing to give yourself daily injections.

Shenzhen, Guangdong
NCT07492563Not yet recruiting
Tirzepatide for weight loss in obesity

This trial tests the safety and effectiveness of tirzepatide, a once-weekly injection, for weight loss in people with obesity. It might be an option if you have a BMI of 27 or higher with weight-related health problems, or a BMI of 35 or higher, and live in or near Asunción, Paraguay.

Asunción
NCT07057310Enrolling by invitation· Phase 4
Weight Loss Drug for Postmenopausal Women With Obesity

This study tests a GLP-1 agonist medication (like Ozempic) to help postmenopausal women lose weight and improve physical and blood vessel health. It focuses on women aged 46–60 with obesity.

Jacksonville, Florida
NCT07481747Recruiting· Phase 3
Weekly injection for weight loss in adults with obesity

This trial tests a once-weekly injection (tirzepatide) versus a placebo to help people who are obese or overweight with related health conditions lose weight. You may qualify if you have tried to lose weight through diet before, but have not been successful.

Shenzhen, Guangdong
NCT07065552Recruiting· Early Phase 1
Tirzepatide for weight-linked endometrial cancer

This trial tests if the weight-loss drug tirzepatide can help people with obesity-related endometrial cancer before their hysterectomy. It may improve surgical outcomes and overall health.

Chapel Hill, North Carolina
NCT07099742Not yet recruiting
Tirzepatide for weight loss in adults with obesity

This study tests if tirzepatide helps people with obesity lose weight, whether or not they have type 2 diabetes. It aims to see how safe and effective the drug is.

Comilla

Hear when a new Nausea and Vomiting trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.